Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Understanding GLP-1 Medications for Diabetes and Obesity
The Controlled Release Drug Delivery Market
Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024
Revolutionizing Parkinson's Treatment: How Laxxon's Extended-Release Levodopa Improves Quality of Life
The Potential of 3D Screen Printing to Combat Counterfeit Medication
Digital Tools In the Healthcare Industry: Addressing Counterfeit Medicine and Safety
Laxxon Medical to Participate in 23rd Annual Needham Virtual Health Conference
Laxxon Medical Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Breaking Down Obesity: Understanding Its Effects and Navigating Treatment Options
3D Screen Printing Offers Unprecedented Anticounterfeiting Strategies for Oral Solid Dosage Forms Feasible for Large Scale Production
Understanding Diabetes: A Comprehensive Guide to Causes, Effects, and Modern Treatments
The Impact of Technology on Pharmaceutical Research: Speed, Efficiency, and Accuracy
What Is the FDA 505b2 Pathway?
Advancing medication with the right DDS: Pulsatile release
Revolutionizing Pharma: 3D Screen Printing and Smart Technologies Shaping the Future of Medicine
Advancing medication with the right DDS: Immediate and delayed release
What is First Pass Metabolism?
Laxxon Medical to Attend BIO-Europe Munich 2023